Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients

Real world evidence is important since most patients cannot be included in randomized clinical trials (RCTs). In a nationwide, cohort of relapsed/refractory multiple myeloma treated with daratumumab (N = 635), we retrospective studied carfilzomib 251). Data were collected by audit medical records. We compared characteristics before (Car-Da; N 150) and after (Da-Car; 101) those not 384). Furthermore, examined effectiveness safety carfilzomib. The group differed from the following parameters: They younger, more up-front high dose melphalan autologous stem cell transplantation (HDM-ASCT)and had relapse within 18 months thereafter, high-risk cytogenetic abnormalities (CA) amplification 1q (amp1q). Car-Da, 30.3% CA 30.1% amp1q Da-Car it was 43.3% 41%, respectively. Car-Da cohort, 34.4% experienced early HDM-ASCT versus 47.4% cohort. percentage very good partial remission higher to (31.7% vs. 17.4%). median duration treatment time next (TNT) Car-Da/Da-Car 4.6/4.3 7.1/4.3 only trend toward superior TNT for found (p 0.06). Toxicity same as reported RCT. A similar poor when used (5.6 months) or (4.9 months). this sequential vice versa, CA, amp1q, HDM-ASCT. Outcome Car-DA outcome equally poor. These should considered new promising strategies.